Open claims and closed claims data serve as vital tools for comprehending patients’ progress and engagements throughout their healthcare voyage. However, which data type proves most advantageous and under what circumstances? Whether the need is to assess the cost-effectiveness of a recently introduced medication or streamline clinical trial recruitment, both open claims data and closed…

As treatment options for patients are constantly evolving, staying ahead of the curve is critical for life science companies and physicians. But with so many options in the market, how can companies gain a competitive advantage with prescribers? By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes. PurpleLab®, a healthcare…

This blog is the fourth and final part in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Of course, the right partner can help life sciences companies keenly focus on doing what they do best. PurpleLab® is a health-tech company driven by…

This blog is part three in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Commercial teams at life sciences companies need to reinvent their go-to-market strategies. In doing so, however, they are apt to face a variety of challenges such as:…

This blog is part two in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  Life sciences companies are operating in a new world, one where new treatments are being developed at breakneck speed, which holds unprecedented promise for patients. However, this…

This blog is part one in a series exploring how to leverage real world data to transform brand planning, launch and management created in collaboration with Fierce Pharma.  The problem: Historical methodologies for targeting, marketing and commercial launch are no longer sufficient to ensure that those patients who could benefit the most from a new…

Healthcare today is evolving into precision medicine, or what the FDA refers to as personalized medicine.  To stay competitive in the constantly shifting healthcare landscape, organizations across the healthcare ecosystem must embrace this targeted approach and leverage the tools needed to make safe decisions for their patients or populations. By unlocking insights provided from advanced…

PurpleLab was selected to present a poster at PMSA 2024 on imputing SDOH information on pharmacy claims. This study was centered around prescription fill rates of Semaglutides in the adolescent population. In December of 2022, the FDA approved adolescents BMI at or above the 95th percentile eligible for a Semaglutide prescription. PurpleLab used a combination…

A large CRO has incorporated PurpleLab data directly into their workflow to support all therapeutic areas and phases of clinical trial work from RWE and pre-award through phase IV and beyond including market access and HEOR work. This strategy has been incorporated for all of their clients.  “The data and services provided by PurpleLab have…